Identification

Name
Trimethadione
Accession Number
DB00347  (APRD00315)
Type
Small Molecule
Groups
Approved
Description

An anticonvulsant effective in absence seizures, but generally reserved for refractory cases because of its toxicity. (From AMA Drug Evaluations Annual, 1994, p378)

Structure
Thumb
Synonyms
  • Trimethadion
  • Triméthadione
  • Trimethadionum
  • Trimethinum
  • Troxidone
External IDs
A 2297 / J2.519D / NSC-15799 / NSC-169503
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
TridioneTablet, chewable150 mg/1OralAbbvie1946-01-25Not applicableUs
International/Other Brands
Minoale (Dainippon Sumitomo) / Tridione
Categories
UNII
R7GV3H6FQ4
CAS number
127-48-0
Weight
Average: 143.1406
Monoisotopic: 143.058243159
Chemical Formula
C6H9NO3
InChI Key
IRYJRGCIQBGHIV-UHFFFAOYSA-N
InChI
InChI=1S/C6H9NO3/c1-6(2)4(8)7(3)5(9)10-6/h1-3H3
IUPAC Name
trimethyl-1,3-oxazolidine-2,4-dione
SMILES
CN1C(=O)OC(C)(C)C1=O

Pharmacology

Indication

Used in the control of absence (petit mal) seizures that are refractory to treatment with other medications.

Associated Conditions
Pharmacodynamics

Paramethadione and trimethadione are anticonvulsants indicated in the control of absence (petit mal) seizures that are refractory to treatment with other medications. Dione anticonvulsants are used in the treatment of epilepsy. They act on the central nervous system (CNS) to reduce the number of seizures.

Mechanism of action

Dione anticonvulsants reduce T-type calcium currents in thalamic neurons, including thalamic relay neurons. It does so via the inhibition of voltage dependent T-type calcium channels. This raises the threshold for repetitive activity in the thalamus, and inhibits corticothalamic transmission. Thus, the abnormal thalamocortical rhythmicity, which is thought to underlie the 3-Hz spike-and-wave discharge seen on electroencephalogram(EEG) with absence seizures, is dampened.

TargetActionsOrganism
AVoltage-dependent T-type calcium channel subunit alpha-1G
inhibitor
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding

90%

Metabolism
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

Symptoms of overdose include clumsiness or unsteadiness, coma, dizziness (severe), drowsiness (severe), nausea (severe), and problems with vision.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylthioamphetamineThe risk or severity of adverse effects can be increased when Trimethadione is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental
3-isobutyl-1-methyl-7H-xanthineTrimethadione may increase the excretion rate of 3-isobutyl-1-methyl-7H-xanthine which could result in a lower serum level and potentially a reduction in efficacy.Experimental
3,4-MethylenedioxyamphetamineThe risk or severity of adverse effects can be increased when 3,4-Methylenedioxyamphetamine is combined with Trimethadione.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Trimethadione.Experimental, Illicit
4-MethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Methoxyamphetamine is combined with Trimethadione.Experimental, Illicit
5-methoxy-N,N-dimethyltryptamineThe risk or severity of adverse effects can be increased when Trimethadione is combined with 5-methoxy-N,N-dimethyltryptamine.Experimental, Illicit
6-O-benzylguanineTrimethadione may increase the excretion rate of 6-O-benzylguanine which could result in a lower serum level and potentially a reduction in efficacy.Investigational
7-DeazaguanineTrimethadione may increase the excretion rate of 7-Deazaguanine which could result in a lower serum level and potentially a reduction in efficacy.Experimental
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Trimethadione.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Trimethadione.Experimental
7,9-DimethylguanineTrimethadione may increase the excretion rate of 7,9-Dimethylguanine which could result in a lower serum level and potentially a reduction in efficacy.Experimental
8-azaguanineTrimethadione may increase the excretion rate of 8-azaguanine which could result in a lower serum level and potentially a reduction in efficacy.Experimental
8-chlorotheophyllineTrimethadione may increase the excretion rate of 8-chlorotheophylline which could result in a lower serum level and potentially a reduction in efficacy.Approved
9-DeazaguanineTrimethadione may increase the excretion rate of 9-Deazaguanine which could result in a lower serum level and potentially a reduction in efficacy.Experimental
9-MethylguanineTrimethadione may increase the excretion rate of 9-Methylguanine which could result in a lower serum level and potentially a reduction in efficacy.Experimental
AbafunginThe therapeutic efficacy of Abafungin can be increased when used in combination with Trimethadione.Investigational
AcefyllineTrimethadione may increase the excretion rate of Acefylline which could result in a lower serum level and potentially a reduction in efficacy.Experimental
AcepromazineThe risk or severity of hypotension can be increased when Acepromazine is combined with Trimethadione.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Trimethadione.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Trimethadione is combined with Acetazolamide.Approved, Vet Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Trimethadione is combined with Acetophenazine.Approved
Acetylglycinamide chloral hydrateThe risk or severity of adverse effects can be increased when Acetylglycinamide chloral hydrate is combined with Trimethadione.Experimental
AcyclovirTrimethadione may increase the excretion rate of Acyclovir which could result in a lower serum level and potentially a reduction in efficacy.Approved
AdinazolamThe risk or severity of adverse effects can be increased when Adinazolam is combined with Trimethadione.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with Trimethadione.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Trimethadione.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Trimethadione is combined with Alaproclate.Experimental
AlbaconazoleThe therapeutic efficacy of Albaconazole can be increased when used in combination with Trimethadione.Investigational
AlcuroniumTrimethadione may increase the neuromuscular blocking activities of Alcuronium.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Trimethadione.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Trimethadione.Approved, Illicit
AlfuzosinThe risk or severity of hypotension can be increased when Alfuzosin is combined with Trimethadione.Approved, Investigational
AlimemazineThe risk or severity of adverse effects can be increased when Trimethadione is combined with Alimemazine.Approved, Vet Approved
AllobarbitalThe risk or severity of adverse effects can be increased when Allobarbital is combined with Trimethadione.Experimental
AllopregnanoloneThe risk or severity of adverse effects can be increased when Allopregnanolone is combined with Trimethadione.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Trimethadione is combined with Almotriptan.Approved, Investigational
AlosetronThe risk or severity of adverse effects can be increased when Trimethadione is combined with Alosetron.Approved, Withdrawn
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Trimethadione.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Trimethadione.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Trimethadione.Approved, Illicit, Investigational
AlprenololThe risk or severity of adverse effects can be increased when Trimethadione is combined with Alprenolol.Approved, Withdrawn
AlverineThe risk or severity of adverse effects can be increased when Trimethadione is combined with Alverine.Approved, Investigational
AmikacinThe risk or severity of adverse effects can be increased when Trimethadione is combined with Amikacin.Approved, Investigational, Vet Approved
AmineptineThe risk or severity of adverse effects can be increased when Amineptine is combined with Trimethadione.Illicit, Withdrawn
AmiodaroneThe metabolism of Trimethadione can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Trimethadione.Approved, Investigational
AmitriptylineThe risk or severity of hypotension can be increased when Amitriptyline is combined with Trimethadione.Approved
AmitriptylinoxideThe risk or severity of adverse effects can be increased when Amitriptylinoxide is combined with Trimethadione.Approved, Investigational
AmobarbitalThe metabolism of Trimethadione can be increased when combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of hypotension can be increased when Amoxapine is combined with Trimethadione.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Trimethadione.Experimental
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Trimethadione.Approved, Illicit, Investigational
Amphotericin BTrimethadione may decrease the nephrotoxic activities of Amphotericin B.Approved, Investigational
AmprenavirThe metabolism of Trimethadione can be decreased when combined with Amprenavir.Approved, Investigational
AniracetamThe risk or severity of adverse effects can be increased when Aniracetam is combined with Trimethadione.Experimental
ApalutamideThe serum concentration of Trimethadione can be decreased when it is combined with Apalutamide.Approved, Investigational
APD791The risk or severity of adverse effects can be increased when Trimethadione is combined with APD791.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Trimethadione is combined with Apomorphine.Approved, Investigational
ApramycinThe risk or severity of adverse effects can be increased when Trimethadione is combined with Apramycin.Experimental, Vet Approved
AprepitantThe serum concentration of Trimethadione can be increased when it is combined with Aprepitant.Approved, Investigational
AprobarbitalThe risk or severity of adverse effects can be increased when Aprobarbital is combined with Trimethadione.Approved, Illicit
ApronalideThe risk or severity of adverse effects can be increased when Apronalide is combined with Trimethadione.Experimental
Arbaclofen PlacarbilThe risk or severity of adverse effects can be increased when Trimethadione is combined with Arbaclofen Placarbil.Investigational
ArbekacinThe risk or severity of adverse effects can be increased when Trimethadione is combined with Arbekacin.Approved, Investigational
AripiprazoleThe risk or severity of hypotension can be increased when Aripiprazole is combined with Trimethadione.Approved, Investigational
Aripiprazole lauroxilThe risk or severity of hypotension can be increased when Aripiprazole lauroxil is combined with Trimethadione.Approved, Investigational
ArotinololThe risk or severity of hypotension can be increased when Arotinolol is combined with Trimethadione.Investigational
AsenapineThe risk or severity of hypotension can be increased when Asenapine is combined with Trimethadione.Approved
AtazanavirThe metabolism of Trimethadione can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe risk or severity of adverse effects can be increased when Atomoxetine is combined with Trimethadione.Approved
AtracuriumTrimethadione may increase the neuromuscular blocking activities of Atracurium.Approved, Experimental, Investigational
Atracurium besylateTrimethadione may increase the neuromuscular blocking activities of Atracurium besylate.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Trimethadione.Investigational, Vet Approved
AzathioprineTrimethadione may increase the excretion rate of Azathioprine which could result in a lower serum level and potentially a reduction in efficacy.Approved
AZD-3043The risk or severity of adverse effects can be increased when AZD-3043 is combined with Trimethadione.Investigational
AzelastineTrimethadione may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Trimethadione.Approved
BamifyllineTrimethadione may increase the excretion rate of Bamifylline which could result in a lower serum level and potentially a reduction in efficacy.Experimental
BarbexacloneThe metabolism of Trimethadione can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Trimethadione can be increased when combined with Barbital.Illicit
BeclamideThe risk or severity of adverse effects can be increased when Trimethadione is combined with Beclamide.Experimental
BekanamycinThe risk or severity of adverse effects can be increased when Trimethadione is combined with Bekanamycin.Experimental
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Trimethadione.Withdrawn
BenmoxinThe risk or severity of adverse effects can be increased when Benmoxin is combined with Trimethadione.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Benperidol is combined with Trimethadione.Approved, Investigational
BenzoctamineThe risk or severity of adverse effects can be increased when Benzoctamine is combined with Trimethadione.Approved
BenzphetamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Trimethadione.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Trimethadione.Approved
BevantololThe risk or severity of hypotension can be increased when Bevantolol is combined with Trimethadione.Approved
BifemelaneThe risk or severity of adverse effects can be increased when Bifemelane is combined with Trimethadione.Experimental
BifeprunoxThe risk or severity of adverse effects can be increased when Trimethadione is combined with Bifeprunox.Investigational
BifonazoleThe therapeutic efficacy of Bifonazole can be increased when used in combination with Trimethadione.Approved, Investigational
BisacodylThe therapeutic efficacy of Bisacodyl can be decreased when used in combination with Trimethadione.Approved
BisoxatinThe therapeutic efficacy of Bisoxatin can be decreased when used in combination with Trimethadione.Approved
BL-1020The risk or severity of adverse effects can be increased when Trimethadione is combined with BL-1020.Investigational
BlonanserinThe risk or severity of adverse effects can be increased when Trimethadione is combined with Blonanserin.Approved, Investigational
BoceprevirThe metabolism of Trimethadione can be decreased when combined with Boceprevir.Approved, Withdrawn
BosentanThe serum concentration of Trimethadione can be decreased when it is combined with Bosentan.Approved, Investigational
Botulinum Toxin Type AThe risk or severity of adverse effects can be increased when Trimethadione is combined with Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BThe risk or severity of adverse effects can be increased when Trimethadione is combined with Botulinum Toxin Type B.Approved, Investigational
BrexpiprazoleThe risk or severity of hypotension can be increased when Brexpiprazole is combined with Trimethadione.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Trimethadione.Approved
BrivaracetamThe risk or severity of adverse effects can be increased when Trimethadione is combined with Brivaracetam.Approved, Investigational
BrofaromineThe risk or severity of adverse effects can be increased when Brofaromine is combined with Trimethadione.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Trimethadione.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Bromisoval is combined with Trimethadione.Experimental
BromocriptineThe risk or severity of hypotension can be increased when Bromocriptine is combined with Trimethadione.Approved, Investigational
BromotheophyllineTrimethadione may increase the excretion rate of Bromotheophylline which could result in a lower serum level and potentially a reduction in efficacy.Approved
BromperidolThe risk or severity of adverse effects can be increased when Bromperidol is combined with Trimethadione.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Trimethadione.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Trimethadione.Approved, Investigational, Withdrawn
BucindololThe risk or severity of hypotension can be increased when Bucindolol is combined with Trimethadione.Investigational
BufotenineThe risk or severity of adverse effects can be increased when Bufotenine is combined with Trimethadione.Experimental, Illicit
BufyllineTrimethadione may increase the excretion rate of Bufylline which could result in a lower serum level and potentially a reduction in efficacy.Experimental
BunazosinThe risk or severity of hypotension can be increased when Bunazosin is combined with Trimethadione.Investigational
BuprenorphineTrimethadione may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of adverse effects can be increased when Bupropion is combined with Trimethadione.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Trimethadione.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Trimethadione.Approved, Illicit
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Trimethadione.Approved, Illicit
ButaperazineThe risk or severity of adverse effects can be increased when Trimethadione is combined with Butaperazine.Experimental
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Trimethadione.Approved, Illicit
ButoconazoleThe therapeutic efficacy of Butoconazole can be increased when used in combination with Trimethadione.Approved
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Trimethadione.Approved, Illicit, Vet Approved
ButriptylineThe risk or severity of adverse effects can be increased when Butriptyline is combined with Trimethadione.Approved
CabergolineThe risk or severity of adverse effects can be increased when Trimethadione is combined with Cabergoline.Approved
CafedrineTrimethadione may increase the excretion rate of Cafedrine which could result in a lower serum level and potentially a reduction in efficacy.Investigational
CaffeineTrimethadione may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.Approved
Calcium AcetateThe therapeutic efficacy of Trimethadione can be decreased when used in combination with Calcium Acetate.Approved, Investigational
Calcium CarbonateThe therapeutic efficacy of Trimethadione can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
Calcium ChlorideThe therapeutic efficacy of Trimethadione can be decreased when used in combination with Calcium Chloride.Approved
Calcium CitrateThe therapeutic efficacy of Trimethadione can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Trimethadione can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Trimethadione can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Trimethadione can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Trimethadione can be decreased when used in combination with Calcium lactate.Approved, Investigational, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Trimethadione can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium levulinateThe therapeutic efficacy of Trimethadione can be decreased when used in combination with Calcium levulinate.Approved, Experimental
Calcium pangamateThe therapeutic efficacy of Trimethadione can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Trimethadione can be decreased when used in combination with Calcium Phosphate.Approved
CamazepamThe risk or severity of adverse effects can be increased when Camazepam is combined with Trimethadione.Approved, Illicit
CannabidiolThe risk or severity of adverse effects can be increased when Trimethadione is combined with Cannabidiol.Approved, Investigational
CannabidivarinThe risk or severity of adverse effects can be increased when Trimethadione is combined with Cannabidivarin.Investigational
CapreomycinThe risk or severity of adverse effects can be increased when Trimethadione is combined with Capreomycin.Approved
CaptodiameThe risk or severity of adverse effects can be increased when Captodiame is combined with Trimethadione.Approved, Investigational
CarbamazepineThe metabolism of Trimethadione can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Trimethadione.Approved
CarboxymethylcelluloseThe therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Trimethadione.Approved, Investigational
CarbromalThe risk or severity of adverse effects can be increased when Carbromal is combined with Trimethadione.Experimental
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Trimethadione.Illicit, Investigational, Vet Approved
CariprazineThe risk or severity of adverse effects can be increased when Trimethadione is combined with Cariprazine.Approved, Investigational
CarisbamateThe risk or severity of adverse effects can be increased when Trimethadione is combined with Carisbamate.Investigational
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Trimethadione.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Caroxazone is combined with Trimethadione.Withdrawn
CarvedilolThe risk or severity of hypotension can be increased when Carvedilol is combined with Trimethadione.Approved, Investigational
Castor oilThe therapeutic efficacy of Castor oil can be decreased when used in combination with Trimethadione.Approved, Investigational, Nutraceutical, Vet Approved
CathinoneThe risk or severity of adverse effects can be increased when Cathinone is combined with Trimethadione.Illicit
CeritinibThe serum concentration of Trimethadione can be increased when it is combined with Ceritinib.Approved
CerlapirdineThe risk or severity of adverse effects can be increased when Trimethadione is combined with Cerlapirdine.Investigational
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Trimethadione.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Trimethadione.Approved, Illicit, Investigational, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Trimethadione.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Trimethadione.Approved, Investigational, Withdrawn
ChloroquineThe risk or severity of adverse effects can be increased when Trimethadione is combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Trimethadione.Approved
ChlorphenesinThe risk or severity of adverse effects can be increased when Trimethadione is combined with Chlorphenesin.Approved, Vet Approved, Withdrawn
ChlorproethazineThe risk or severity of adverse effects can be increased when Trimethadione is combined with Chlorproethazine.Experimental
ChlorpromazineThe risk or severity of hypotension can be increased when Chlorpromazine is combined with Trimethadione.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Trimethadione.Approved, Investigational, Withdrawn
ChlortetracyclineThe risk or severity of adverse effects can be increased when Trimethadione is combined with Chlortetracycline.Approved, Investigational, Vet Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Trimethadione.Approved
CilansetronThe risk or severity of adverse effects can be increased when Trimethadione is combined with Cilansetron.Investigational
CimetidineThe serum concentration of Trimethadione can be increased when it is combined with Cimetidine.Approved, Investigational
CinitaprideThe risk or severity of adverse effects can be increased when Trimethadione is combined with Cinitapride.Approved, Investigational
CinolazepamThe risk or severity of adverse effects can be increased when Cinolazepam is combined with Trimethadione.Approved
CisaprideThe risk or severity of adverse effects can be increased when Trimethadione is combined with Cisapride.Approved, Investigational, Withdrawn
CisatracuriumTrimethadione may increase the neuromuscular blocking activities of Cisatracurium.Approved
CitalopramThe risk or severity of adverse effects can be increased when Trimethadione is combined with Citalopram.Approved
ClarithromycinThe metabolism of Trimethadione can be decreased when combined with Clarithromycin.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Trimethadione.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Trimethadione.Approved
ClindamycinThe risk or severity of adverse effects can be increased when Trimethadione is combined with Clindamycin.Approved, Vet Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Trimethadione.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Trimethadione.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Trimethadione.Approved, Investigational, Vet Approved
ClomocyclineThe risk or severity of adverse effects can be increased when Trimethadione is combined with Clomocycline.Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Trimethadione.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Trimethadione.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Clopenthixol is combined with Trimethadione.Experimental
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Trimethadione.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Trimethadione.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Clothiapine is combined with Trimethadione.Experimental
ClotiazepamThe risk or severity of adverse effects can be increased when Clotiazepam is combined with Trimethadione.Approved, Illicit
ClotrimazoleThe metabolism of Trimethadione can be decreased when combined with Clotrimazole.Approved, Vet Approved
CloxazolamThe risk or severity of adverse effects can be increased when Cloxazolam is combined with Trimethadione.Approved, Investigational
ClozapineThe risk or severity of hypotension can be increased when Clozapine is combined with Trimethadione.Approved
CobicistatThe metabolism of Trimethadione can be decreased when combined with Cobicistat.Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Trimethadione.Approved, Illicit
ColistimethateThe risk or severity of adverse effects can be increased when Trimethadione is combined with Colistimethate.Approved, Vet Approved
ColistinThe risk or severity of adverse effects can be increased when Trimethadione is combined with Colistin.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Trimethadione.Approved, Investigational
CrizotinibThe metabolism of Trimethadione can be decreased when combined with Crizotinib.Approved
CurcuminThe metabolism of Trimethadione can be decreased when combined with Curcumin.Approved, Investigational
CyamemazineThe risk or severity of adverse effects can be increased when Cyamemazine is combined with Trimethadione.Approved
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Trimethadione.Approved
CyclobarbitalThe risk or severity of adverse effects can be increased when Cyclobarbital is combined with Trimethadione.Experimental
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Trimethadione.Approved
CyclopropaneThe risk or severity of adverse effects can be increased when Cyclopropane is combined with Trimethadione.Experimental
CyclosporineThe risk or severity of adverse effects can be increased when Trimethadione is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Trimethadione.Approved
DabrafenibThe serum concentration of Trimethadione can be decreased when it is combined with Dabrafenib.Approved, Investigational
DanazolThe metabolism of Trimethadione can be decreased when combined with Danazol.Approved
DanthronThe therapeutic efficacy of Danthron can be decreased when used in combination with Trimethadione.Approved, Investigational, Withdrawn
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Trimethadione.Approved, Investigational
DapiprazoleThe risk or severity of hypotension can be increased when Dapiprazole is combined with Trimethadione.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Trimethadione is combined with Dapoxetine.Investigational
DarunavirThe metabolism of Trimethadione can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Trimethadione can be increased when it is combined with Dasatinib.Approved, Investigational
DeanolThe risk or severity of adverse effects can be increased when Deanol is combined with Trimethadione.Experimental
DecamethoniumThe risk or severity of adverse effects can be increased when Trimethadione is combined with Decamethonium.Approved
DeferasiroxThe serum concentration of Trimethadione can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Trimethadione can be decreased when combined with Delavirdine.Approved
DelorazepamThe risk or severity of adverse effects can be increased when Delorazepam is combined with Trimethadione.Approved, Illicit, Investigational
DemeclocyclineThe risk or severity of adverse effects can be increased when Trimethadione is combined with Demeclocycline.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Deramciclane is combined with Trimethadione.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Trimethadione.Approved
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Trimethadione.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Trimethadione.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Trimethadione is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Trimethadione.Vet Approved
DexamethasoneThe serum concentration of Trimethadione can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Trimethadione.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Trimethadione.Approved, Vet Approved
DexmethylphenidateThe risk or severity of adverse effects can be increased when Trimethadione is combined with Dexmethylphenidate.Approved, Investigational
DextofisopamThe risk or severity of adverse effects can be increased when Dextofisopam is combined with Trimethadione.Investigational
DextromethorphanThe risk or severity of adverse effects can be increased when Trimethadione is combined with Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Trimethadione.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Trimethadione.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Trimethadione.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Trimethadione.Approved, Illicit, Investigational, Vet Approved
DibekacinThe risk or severity of adverse effects can be increased when Trimethadione is combined with Dibekacin.Experimental
DibenzepinThe risk or severity of adverse effects can be increased when Dibenzepin is combined with Trimethadione.Experimental
DichloralphenazoneThe risk or severity of adverse effects can be increased when Dichloralphenazone is combined with Trimethadione.Approved, Illicit
Diethyl etherThe risk or severity of adverse effects can be increased when Diethyl ether is combined with Trimethadione.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Trimethadione.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Trimethadione.Approved, Illicit
DihydroergotamineThe risk or severity of hypotension can be increased when Dihydroergotamine is combined with Trimethadione.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Trimethadione.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Trimethadione.Experimental, Illicit
DihydrostreptomycinThe risk or severity of adverse effects can be increased when Trimethadione is combined with Dihydrostreptomycin.Investigational, Vet Approved
DiltiazemThe metabolism of Trimethadione can be decreased when combined with Diltiazem.Approved, Investigational
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Trimethadione.Approved
DimetacrineThe risk or severity of adverse effects can be increased when Dimetacrine is combined with Trimethadione.Approved, Withdrawn
DimethyltryptamineThe risk or severity of adverse effects can be increased when Dimethyltryptamine is combined with Trimethadione.Experimental, Illicit
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Trimethadione.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Trimethadione.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Dixyrazine is combined with Trimethadione.Experimental
DocusateThe therapeutic efficacy of Docusate can be decreased when used in combination with Trimethadione.Approved
DolasetronThe risk or severity of adverse effects can be increased when Trimethadione is combined with Dolasetron.Approved, Investigational
Domoic AcidThe risk or severity of adverse effects can be increased when Trimethadione is combined with Domoic Acid.Experimental
DonepezilThe risk or severity of adverse effects can be increased when Trimethadione is combined with Donepezil.Approved
DopamineThe risk or severity of adverse effects can be increased when Trimethadione is combined with Dopamine.Approved
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Trimethadione.Vet Approved
DosulepinThe risk or severity of adverse effects can be increased when Dosulepin is combined with Trimethadione.Approved
DotarizineThe risk or severity of adverse effects can be increased when Trimethadione is combined with Dotarizine.Investigational
DoxacuriumTrimethadione may increase the neuromuscular blocking activities of Doxacurium.Approved
DoxazosinThe risk or severity of hypotension can be increased when Doxazosin is combined with Trimethadione.Approved
DoxefazepamThe risk or severity of adverse effects can be increased when Doxefazepam is combined with Trimethadione.Experimental
DoxepinThe risk or severity of hypotension can be increased when Doxepin is combined with Trimethadione.Approved, Investigational
DoxofyllineTrimethadione may increase the excretion rate of Doxofylline which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
DoxycyclineThe metabolism of Trimethadione can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Trimethadione.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Trimethadione.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Trimethadione.Approved, Illicit
DronedaroneThe risk or severity of hypotension can be increased when Dronedarone is combined with Trimethadione.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Trimethadione.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Trimethadione.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Trimethadione is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Trimethadione.Approved
EconazoleThe therapeutic efficacy of Econazole can be increased when used in combination with Trimethadione.Approved
EcopipamThe risk or severity of adverse effects can be increased when Ecopipam is combined with Trimethadione.Investigational
EdivoxetineThe risk or severity of adverse effects can be increased when Edivoxetine is combined with Trimethadione.Investigational
EfavirenzThe serum concentration of Trimethadione can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe therapeutic efficacy of Efinaconazole can be increased when used in combination with Trimethadione.Approved
EletriptanThe risk or severity of adverse effects can be increased when Trimethadione is combined with Eletriptan.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Eltanolone is combined with Trimethadione.Investigational
EltoprazineThe risk or severity of adverse effects can be increased when Trimethadione is combined with Eltoprazine.Investigational
EmeproniumThe risk or severity of adverse effects can be increased when Emepronium is combined with Trimethadione.Experimental
EmylcamateThe risk or severity of adverse effects can be increased when Emylcamate is combined with Trimethadione.Experimental
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Trimethadione.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Trimethadione.Approved, Investigational
EntecavirTrimethadione may increase the excretion rate of Entecavir which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
EnzalutamideThe serum concentration of Trimethadione can be decreased when it is combined with Enzalutamide.Approved
EperisoneThe risk or severity of adverse effects can be increased when Trimethadione is combined with Eperisone.Approved, Investigational
EpinastineThe risk or severity of adverse effects can be increased when Trimethadione is combined with Epinastine.Approved, Investigational
EplivanserinThe risk or severity of adverse effects can be increased when Trimethadione is combined with Eplivanserin.Investigational
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Trimethadione is combined with Ergoloid mesylate.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Trimethadione is combined with Ergonovine.Approved
ErgotamineThe risk or severity of hypotension can be increased when Ergotamine is combined with Trimethadione.Approved
ErythromycinThe metabolism of Trimethadione can be decreased when combined with Erythromycin.Approved, Investigational, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Trimethadione is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe risk or severity of adverse effects can be increased when Trimethadione is combined with Eslicarbazepine acetate.Approved
EsmirtazapineThe risk or severity of adverse effects can be increased when Esmirtazapine is combined with Trimethadione.Investigational
EsreboxetineThe risk or severity of adverse effects can be increased when Trimethadione is combined with Esreboxetine.Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Trimethadione.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Trimethadione.Approved, Investigational
Etacrynic acidThe risk or severity of adverse effects can be increased when Trimethadione is combined with Etacrynic acid.Approved, Investigational
EtamiphyllineTrimethadione may increase the excretion rate of Etamiphylline which could result in a lower serum level and potentially a reduction in efficacy.Experimental
EthadioneThe risk or severity of adverse effects can be increased when Trimethadione is combined with Ethadione.Experimental
EthanolTrimethadione may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Trimethadione.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Trimethadione.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Trimethadione.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Trimethadione.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Ethyl chloride is combined with Trimethadione.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Trimethadione.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Trimethadione.Approved, Illicit
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Trimethadione.Investigational, Withdrawn
EtiracetamThe risk or severity of adverse effects can be increased when Trimethadione is combined with Etiracetam.Investigational
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Trimethadione.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Trimethadione.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Etoperidone is combined with Trimethadione.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Trimethadione is combined with Etorphine.Illicit, Vet Approved
EtravirineThe serum concentration of Trimethadione can be decreased when it is combined with Etravirine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Trimethadione.Approved, Investigational
FabomotizoleThe risk or severity of adverse effects can be increased when Fabomotizole is combined with Trimethadione.Experimental
Fazadinium bromideThe risk or severity of adverse effects can be increased when Trimethadione is combined with Fazadinium bromide.Experimental
FebarbamateThe risk or severity of adverse effects can be increased when Trimethadione is combined with Febarbamate.Experimental
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Trimethadione.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Trimethadione.Approved, Illicit, Withdrawn
FenethyllineTrimethadione may increase the excretion rate of Fenethylline which could result in a lower serum level and potentially a reduction in efficacy.Approved
FenfluramineThe risk or severity of adverse effects can be increased when Trimethadione is combined with Fenfluramine.Approved, Illicit, Investigational, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Trimethadione.Approved, Illicit, Investigational, Vet Approved
FenticonazoleThe therapeutic efficacy of Fenticonazole can be increased when used in combination with Trimethadione.Experimental
FenyramidolThe risk or severity of adverse effects can be increased when Trimethadione is combined with Fenyramidol.Experimental
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Trimethadione.Approved, Investigational
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Trimethadione.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Fluanisone is combined with Trimethadione.Experimental
FluconazoleThe metabolism of Trimethadione can be decreased when combined with Fluconazole.Approved, Investigational
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Trimethadione.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Trimethadione.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Trimethadione.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Trimethadione is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of hypotension can be increased when Flupentixol is combined with Trimethadione.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Trimethadione.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Trimethadione.Approved, Illicit, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Trimethadione.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Trimethadione.Approved
FlutrimazoleThe therapeutic efficacy of Flutrimazole can be increased when used in combination with Trimethadione.Experimental
FluvoxamineThe risk or severity of adverse effects can be increased when Trimethadione is combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Trimethadione can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Trimethadione can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Trimethadione.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Trimethadione.Approved, Illicit, Investigational
FramycetinThe risk or severity of adverse effects can be increased when Trimethadione is combined with Framycetin.Approved
FrovatriptanThe risk or severity of adverse effects can be increased when Trimethadione is combined with Frovatriptan.Approved, Investigational
FurafyllineTrimethadione may increase the excretion rate of Furafylline which could result in a lower serum level and potentially a reduction in efficacy.Experimental
FurazolidoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Trimethadione.Approved, Investigational, Vet Approved
Fusidic AcidThe serum concentration of Trimethadione can be increased when it is combined with Fusidic Acid.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Trimethadione.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Trimethadione.Approved, Investigational
GaboxadolThe risk or severity of adverse effects can be increased when Trimethadione is combined with Gaboxadol.Investigational
GallamineTrimethadione may increase the neuromuscular blocking activities of Gallamine.Experimental
Gallamine TriethiodideTrimethadione may increase the neuromuscular blocking activities of Gallamine Triethiodide.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Trimethadione.Approved, Illicit, Investigational
GanciclovirTrimethadione may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
Gantacurium ChlorideThe risk or severity of adverse effects can be increased when Trimethadione is combined with Gantacurium Chloride.Investigational
GedocarnilThe risk or severity of adverse effects can be increased when Gedocarnil is combined with Trimethadione.Experimental
GeneticinThe risk or severity of adverse effects can be increased when Trimethadione is combined with Geneticin.Experimental
GentamicinThe risk or severity of adverse effects can be increased when Trimethadione is combined with Gentamicin.Approved, Vet Approved
GENTAMICIN C1AThe risk or severity of adverse effects can be increased when Trimethadione is combined with GENTAMICIN C1A.Experimental
GepironeThe risk or severity of adverse effects can be increased when Gepirone is combined with Trimethadione.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Trimethadione.Approved, Illicit
GlycerinThe therapeutic efficacy of Glycerin can be decreased when used in combination with Trimethadione.Approved, Investigational
GranisetronThe risk or severity of adverse effects can be increased when Trimethadione is combined with Granisetron.Approved, Investigational
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Trimethadione.Approved, Investigational
GuanineTrimethadione may increase the excretion rate of Guanine which could result in a lower serum level and potentially a reduction in efficacy.Experimental
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Trimethadione.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Trimethadione.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Trimethadione.Approved, Vet Approved
HarmalineThe risk or severity of adverse effects can be increased when Harmaline is combined with Trimethadione.Experimental
HeptabarbitalThe risk or severity of adverse effects can be increased when Heptabarbital is combined with Trimethadione.Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Trimethadione.Approved, Illicit, Investigational
HexafluroniumThe risk or severity of adverse effects can be increased when Trimethadione is combined with Hexafluronium.Approved
HexamethoniumThe risk or severity of adverse effects can be increased when Trimethadione is combined with Hexamethonium.Experimental
HexapropymateThe risk or severity of adverse effects can be increased when Hexapropymate is combined with Trimethadione.Experimental
HexobarbitalThe metabolism of Trimethadione can be increased when combined with Hexobarbital.Approved
HydracarbazineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Trimethadione.Experimental
HydrocodoneTrimethadione may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Trimethadione.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Trimethadione.Approved
Hygromycin BThe risk or severity of adverse effects can be increased when Trimethadione is combined with Hygromycin B.Vet Approved
HypericinThe risk or severity of adverse effects can be increased when Hypericin is combined with Trimethadione.Investigational
HypoxanthineTrimethadione may increase the excretion rate of Hypoxanthine which could result in a lower serum level and potentially a reduction in efficacy.Experimental
IdalopirdineThe risk or severity of adverse effects can be increased when Trimethadione is combined with Idalopirdine.Investigational
IdelalisibThe metabolism of Trimethadione can be decreased when combined with Idelalisib.Approved
IfenprodilThe risk or severity of adverse effects can be increased when Trimethadione is combined with Ifenprodil.Approved, Investigational, Withdrawn
IferanserinThe risk or severity of adverse effects can be increased when Trimethadione is combined with Iferanserin.Investigational
IloperidoneThe risk or severity of hypotension can be increased when Iloperidone is combined with Trimethadione.Approved
ImagabalinThe risk or severity of adverse effects can be increased when Imagabalin is combined with Trimethadione.Investigational
ImatinibThe metabolism of Trimethadione can be decreased when combined with Imatinib.Approved
ImipramineThe risk or severity of hypotension can be increased when Imipramine is combined with Trimethadione.Approved
Imipramine oxideThe risk or severity of adverse effects can be increased when Imipramine oxide is combined with Trimethadione.Experimental
IndalpineThe risk or severity of adverse effects can be increased when Trimethadione is combined with Indalpine.Investigational, Withdrawn
IndinavirThe metabolism of Trimethadione can be decreased when combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Indiplon is combined with Trimethadione.Investigational
IndoraminThe risk or severity of hypotension can be increased when Indoramin is combined with Trimethadione.Withdrawn
IprazochromeThe risk or severity of adverse effects can be increased when Trimethadione is combined with Iprazochrome.Experimental
IprindoleThe risk or severity of adverse effects can be increased when Iprindole is combined with Trimethadione.Experimental
IproclozideThe risk or severity of adverse effects can be increased when Iproclozide is combined with Trimethadione.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Iproniazid is combined with Trimethadione.Withdrawn
IsavuconazoleThe serum concentration of Trimethadione can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Trimethadione can be decreased when combined with Isavuconazonium.Approved, Investigational
IsepamicinThe risk or severity of adverse effects can be increased when Trimethadione is combined with Isepamicin.Experimental
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Trimethadione.Approved
IsoconazoleThe therapeutic efficacy of Isoconazole can be increased when used in combination with Trimethadione.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Trimethadione.Approved, Vet Approved
IsoniazidThe metabolism of Trimethadione can be decreased when combined with Isoniazid.Approved, Investigational
ItraconazoleThe metabolism of Trimethadione can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Trimethadione can be increased when it is combined with Ivacaftor.Approved
KanamycinThe risk or severity of adverse effects can be increased when Trimethadione is combined with Kanamycin.Approved, Investigational, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Trimethadione.Approved, Vet Approved
KetanserinThe risk or severity of adverse effects can be increased when Trimethadione is combined with Ketanserin.Investigational
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Trimethadione.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Trimethadione.Approved, Investigational
KetoconazoleThe metabolism of Trimethadione can be decreased when combined with Ketoconazole.Approved, Investigational
L-TryptophanThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Trimethadione.Approved, Nutraceutical, Withdrawn
LabetalolThe risk or severity of hypotension can be increased when Labetalol is combined with Trimethadione.Approved
LacosamideThe risk or severity of adverse effects can be increased when Trimethadione is combined with Lacosamide.Approved
LactitolThe therapeutic efficacy of Lactitol can be decreased when used in combination with Trimethadione.Investigational
LactuloseThe therapeutic efficacy of Lactulose can be decreased when used in combination with Trimethadione.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Trimethadione.Approved, Investigational
LanicemineThe risk or severity of adverse effects can be increased when Lanicemine is combined with Trimethadione.Investigational
LasmiditanThe risk or severity of adverse effects can be increased when Trimethadione is combined with Lasmiditan.Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Trimethadione.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Trimethadione is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Trimethadione.Approved
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Trimethadione.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Trimethadione.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Trimethadione is combined with Levomilnacipran.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Trimethadione.Approved
LinaclotideThe therapeutic efficacy of Linaclotide can be decreased when used in combination with Trimethadione.Approved
LincomycinThe risk or severity of adverse effects can be increased when Trimethadione is combined with Lincomycin.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Trimethadione is combined with Linezolid.Approved, Investigational
LisofyllineTrimethadione may increase the excretion rate of Lisofylline which could result in a lower serum level and potentially a reduction in efficacy.Investigational
LisurideThe risk or severity of adverse effects can be increased when Trimethadione is combined with Lisuride.Approved, Investigational
Lithium carbonateThe risk or severity of adverse effects can be increased when Trimethadione is combined with Lithium carbonate.Approved
Lithium cationThe risk or severity of adverse effects can be increased when Lithium cation is combined with Trimethadione.Experimental
LobucavirTrimethadione may increase the excretion rate of Lobucavir which could result in a lower serum level and potentially a reduction in efficacy.Investigational
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Trimethadione.Illicit
LofepramineThe risk or severity of adverse effects can be increased when Lofepramine is combined with Trimethadione.Experimental
LofexidineThe therapeutic efficacy of Trimethadione can be increased when used in combination with Lofexidine.Approved, Investigational
LopinavirThe metabolism of Trimethadione can be decreased when combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Loprazolam is combined with Trimethadione.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Trimethadione.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Trimethadione.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Trimethadione is combined with Lorcaserin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Trimethadione.Approved
LorpiprazoleThe serum concentration of Trimethadione can be increased when it is combined with Lorpiprazole.Approved
LortalamineThe risk or severity of adverse effects can be increased when Trimethadione is combined with Lortalamine.Experimental
LovastatinThe metabolism of Trimethadione can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Trimethadione.Approved
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Trimethadione.Approved, Investigational
LuliconazoleThe serum concentration of Trimethadione can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Trimethadione can be increased when combined with Lumacaftor.Approved
LumateperoneThe risk or severity of adverse effects can be increased when Trimethadione is combined with Lumateperone.Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Trimethadione.Approved, Investigational
LymecyclineThe risk or severity of adverse effects can be increased when Trimethadione is combined with Lymecycline.Approved, Investigational
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Trimethadione.Illicit, Investigational, Withdrawn
m-ChlorophenylpiperazineThe risk or severity of adverse effects can be increased when Trimethadione is combined with m-Chlorophenylpiperazine.Investigational
Magnesium acetateThe risk or severity of adverse effects can be increased when Trimethadione is combined with Magnesium acetate.Approved
Magnesium acetate tetrahydrateThe risk or severity of adverse effects can be increased when Trimethadione is combined with Magnesium acetate tetrahydrate.Approved
Magnesium Aluminum SilicateThe risk or severity of adverse effects can be increased when Trimethadione is combined with Magnesium Aluminum Silicate.Approved
Magnesium aspartateThe risk or severity of adverse effects can be increased when Trimethadione is combined with Magnesium aspartate.Experimental
Magnesium carbonateThe risk or severity of adverse effects can be increased when Trimethadione is combined with Magnesium carbonate.Approved, Investigational
Magnesium cationThe risk or severity of adverse effects can be increased when Trimethadione is combined with Magnesium cation.Approved, Nutraceutical
Magnesium chlorideThe risk or severity of adverse effects can be increased when Trimethadione is combined with Magnesium chloride.Approved
Magnesium citrateThe risk or severity of adverse effects can be increased when Trimethadione is combined with Magnesium citrate.Approved
Magnesium gluconateThe risk or severity of adverse effects can be increased when Trimethadione is combined with Magnesium gluconate.Approved, Investigational
Magnesium glycinateThe risk or severity of adverse effects can be increased when Trimethadione is combined with Magnesium glycinate.Approved
Magnesium hydroxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Trimethadione is combined with Magnesium hydroxide.Approved, Investigational
Magnesium orotateThe risk or severity of adverse effects can be increased when Trimethadione is combined with Magnesium orotate.Experimental
Magnesium oxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Trimethadione is combined with Magnesium oxide.Approved
Magnesium peroxideThe therapeutic efficacy of Magnesium peroxide can be decreased when used in combination with Trimethadione.Experimental
Magnesium phosphateThe risk or severity of adverse effects can be increased when Trimethadione is combined with Magnesium phosphate.Experimental
Magnesium salicylateThe risk or severity of hypotension and neuromuscular blockade can be increased when Trimethadione is combined with Magnesium salicylate.Approved
Magnesium silicateThe risk or severity of adverse effects can be increased when Trimethadione is combined with Magnesium silicate.Approved
Magnesium stearateThe risk or severity of adverse effects can be increased when Trimethadione is combined with Magnesium stearate.Investigational
Magnesium sulfateThe therapeutic efficacy of Trimethadione can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateThe risk or severity of adverse effects can be increased when Trimethadione is combined with Magnesium Trisilicate.Approved
MannitolThe therapeutic efficacy of Mannitol can be decreased when used in combination with Trimethadione.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Trimethadione.Approved, Investigational
MazindolThe risk or severity of adverse effects can be increased when Mazindol is combined with Trimethadione.Approved, Investigational
MebanazineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Trimethadione.Withdrawn
MebicarThe risk or severity of adverse effects can be increased when Mebicar is combined with Trimethadione.Experimental
MebutamateThe risk or severity of adverse effects can be increased when Mebutamate is combined with Trimethadione.Approved
MecamylamineThe risk or severity of adverse effects can be increased when Trimethadione is combined with Mecamylamine.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Trimethadione.Approved
MedazepamThe risk or severity of adverse effects can be increased when Medazepam is combined with Trimethadione.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Trimethadione.Vet Approved
MedifoxamineThe risk or severity of adverse effects can be increased when Medifoxamine is combined with Trimethadione.Experimental
MefloquineThe therapeutic efficacy of Trimethadione can be decreased when used in combination with Mefloquine.Approved, Investigational
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Trimethadione.Approved, Nutraceutical, Vet Approved
MelitracenThe risk or severity of adverse effects can be increased when Melitracen is combined with Trimethadione.Experimental, Investigational
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Trimethadione.Approved, Investigational
MephenesinThe risk or severity of adverse effects can be increased when Trimethadione is combined with Mephenesin.Approved
MephenoxaloneThe risk or severity of adverse effects can be increased when Mephenoxalone is combined with Trimethadione.Experimental
MephenytoinThe risk or severity of adverse effects can be increased when Trimethadione is combined with Mephenytoin.Investigational, Withdrawn
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Trimethadione.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Trimethadione.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Trimethadione.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Trimethadione.Approved
MetergolineThe risk or severity of adverse effects can be increased when Trimethadione is combined with Metergoline.Experimental
MethacyclineThe risk or severity of adverse effects can be increased when Trimethadione is combined with Methacycline.Approved, Investigational
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Trimethadione.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Trimethadione.Approved, Illicit
MethamphetamineThe risk or severity of adverse effects can be increased when Methamphetamine is combined with Trimethadione.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Trimethadione.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Trimethadione.Illicit, Withdrawn
MetharbitalThe risk or severity of adverse effects can be increased when Trimethadione is combined with Metharbital.Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Trimethadione.Approved, Vet Approved
MethohexitalThe metabolism of Trimethadione can be increased when combined with Methohexital.Approved
MethotrimeprazineTrimethadione may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Trimethadione.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Trimethadione.Approved
Methyl celluloseThe therapeutic efficacy of Methyl cellulose can be decreased when used in combination with Trimethadione.Approved
Methylene blueThe risk or severity of adverse effects can be increased when Methylene blue is combined with Trimethadione.Approved, Investigational
MethylpentynolThe risk or severity of adverse effects can be increased when Methylpentynol is combined with Trimethadione.Experimental
MethylphenidateThe risk or severity of adverse effects can be increased when Trimethadione is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe metabolism of Trimethadione can be increased when combined with Methylphenobarbital.Approved
MethyprylonThe risk or severity of adverse effects can be increased when Methyprylon is combined with Trimethadione.Approved, Illicit, Withdrawn
MethysergideThe risk or severity of adverse effects can be increased when Trimethadione is combined with Methysergide.Approved
MetocurineTrimethadione may increase the neuromuscular blocking activities of Metocurine.Approved
Metocurine IodideTrimethadione may increase the neuromuscular blocking activities of Metocurine Iodide.Approved, Withdrawn
MetyrosineTrimethadione may increase the sedative activities of Metyrosine.Approved
MianserinThe therapeutic efficacy of Trimethadione can be decreased when used in combination with Mianserin.Approved, Investigational
MibefradilThe metabolism of Trimethadione can be decreased when combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe metabolism of Trimethadione can be decreased when combined with Miconazole.Approved, Investigational, Vet Approved
MicronomicinThe risk or severity of adverse effects can be increased when Trimethadione is combined with Micronomicin.Experimental
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Trimethadione.Approved, Illicit
MidomafetamineThe risk or severity of adverse effects can be increased when Midomafetamine is combined with Trimethadione.Experimental, Illicit, Investigational
MifepristoneThe serum concentration of Trimethadione can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Trimethadione is combined with Milnacipran.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Minaprine is combined with Trimethadione.Approved
Mineral oilThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Trimethadione.Approved, Vet Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Trimethadione.Approved, Investigational
MirtazapineTrimethadione may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Trimethadione can be decreased when it is combined with Mitotane.Approved
MivacuriumTrimethadione may increase the neuromuscular blocking activities of Mivacurium.Approved
MK-212The risk or severity of adverse effects can be increased when Trimethadione is combined with MK-212.Investigational
MMDAThe risk or severity of adverse effects can be increased when Trimethadione is combined with MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Trimethadione.Approved, Investigational
ModafinilThe serum concentration of Trimethadione can be decreased when it is combined with Modafinil.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Trimethadione.Approved
MoperoneThe risk or severity of adverse effects can be increased when Trimethadione is combined with Moperone.Experimental
MoricizineThe risk or severity of adverse effects can be increased when Trimethadione is combined with Moricizine.Approved, Investigational, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Trimethadione.Approved, Investigational
MosapramineThe risk or severity of adverse effects can be increased when Trimethadione is combined with Mosapramine.Experimental
MosaprideThe risk or severity of adverse effects can be increased when Trimethadione is combined with Mosapride.Investigational
MRK-409The risk or severity of adverse effects can be increased when MRK-409 is combined with Trimethadione.Experimental
N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamineThe risk or severity of adverse effects can be increased when Trimethadione is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Trimethadione.Approved, Investigational
NafcillinThe therapeutic efficacy of Trimethadione can be decreased when used in combination with Nafcillin.Approved, Investigational
NaftidrofurylThe risk or severity of adverse effects can be increased when Trimethadione is combined with Naftidrofuryl.Experimental
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Trimethadione.Approved
NaloxoneThe metabolism of Trimethadione can be decreased when combined with Naloxone.Approved, Vet Approved
NaluzotanThe risk or severity of adverse effects can be increased when Trimethadione is combined with Naluzotan.Investigational
NaratriptanThe risk or severity of adverse effects can be increased when Trimethadione is combined with Naratriptan.Approved, Investigational
NaronaprideThe risk or severity of adverse effects can be increased when Trimethadione is combined with Naronapride.Investigational
NeamineThe risk or severity of adverse effects can be increased when Trimethadione is combined with Neamine.Experimental
NefazodoneThe risk or severity of adverse effects can be increased when Trimethadione is combined with Nefazodone.Approved, Withdrawn
NefiracetamThe risk or severity of adverse effects can be increased when Nefiracetam is combined with Trimethadione.Investigational
NelfinavirThe metabolism of Trimethadione can be decreased when combined with Nelfinavir.Approved
NeocitrullamonThe risk or severity of adverse effects can be increased when Trimethadione is combined with Neocitrullamon.Experimental
NeomycinThe risk or severity of adverse effects can be increased when Trimethadione is combined with Neomycin.Approved, Vet Approved
NeosaxitoxinThe risk or severity of adverse effects can be increased when Trimethadione is combined with Neosaxitoxin.Investigational
NetilmicinThe risk or severity of adverse effects can be increased when Trimethadione is combined with Netilmicin.Approved, Investigational
NetupitantThe serum concentration of Trimethadione can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Trimethadione can be increased when combined with Nevirapine.Approved
NialamideThe risk or severity of adverse effects can be increased when Nialamide is combined with Trimethadione.Withdrawn
NiaprazineThe risk or severity of adverse effects can be increased when Niaprazine is combined with Trimethadione.Experimental
NicardipineThe risk or severity of hypotension can be increased when Nicardipine is combined with Trimethadione.Approved, Investigational
NicergolineThe risk or severity of hypotension can be increased when Nicergoline is combined with Trimethadione.Approved, Investigational
NiguldipineThe risk or severity of hypotension can be increased when Niguldipine is combined with Trimethadione.Experimental
NilotinibThe metabolism of Trimethadione can be decreased when combined with Nilotinib.Approved, Investigational
NisoxetineThe risk or severity of adverse effects can be increased when Trimethadione is combined with Nisoxetine.Experimental
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Trimethadione.Approved
NitroprussideTrimethadione may increase the hypotensive activities of Nitroprusside.Approved, Investigational
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Trimethadione.Approved, Vet Approved
NomifensineThe risk or severity of adverse effects can be increased when Nomifensine is combined with Trimethadione.Withdrawn
NordazepamThe risk or severity of adverse effects can be increased when Nordazepam is combined with Trimethadione.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Trimethadione.Approved, Illicit
NortriptylineThe risk or severity of hypotension can be increased when Nortriptyline is combined with Trimethadione.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Octamoxin is combined with Trimethadione.Withdrawn
OlanzapineThe risk or severity of hypotension can be increased when Olanzapine is combined with Trimethadione.Approved, Investigational
OlaparibThe metabolism of Trimethadione can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Trimethadione.Approved
OmoconazoleThe therapeutic efficacy of Omoconazole can be increased when used in combination with Trimethadione.Experimental
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Trimethadione.Approved
OpipramolThe risk or severity of adverse effects can be increased when Opipramol is combined with Trimethadione.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Trimethadione.Approved, Illicit
OrlistatOrlistat can cause a decrease in the absorption of Trimethadione resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
OrphenadrineTrimethadione may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OrvepitantThe risk or severity of adverse effects can be increased when Orvepitant is combined with Trimethadione.Investigational
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Trimethadione.Investigational
OsimertinibThe serum concentration of Trimethadione can be increased when it is combined with Osimertinib.Approved
OxaflozaneThe risk or severity of adverse effects can be increased when Oxaflozane is combined with Trimethadione.Experimental
OxaprotilineThe risk or severity of adverse effects can be increased when Oxaprotiline is combined with Trimethadione.Experimental
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Trimethadione.Approved
OxcarbazepineThe risk or severity of adverse effects can be increased when Trimethadione is combined with Oxcarbazepine.Approved
OxiconazoleThe therapeutic efficacy of Oxiconazole can be increased when used in combination with Trimethadione.Approved
OxiracetamThe risk or severity of adverse effects can be increased when Oxiracetam is combined with Trimethadione.Experimental
OxitriptanThe risk or severity of adverse effects can be increased when Oxitriptan is combined with Trimethadione.Approved, Investigational, Nutraceutical
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Trimethadione.Approved
OxtriphyllineTrimethadione may increase the excretion rate of Oxtriphylline which could result in a lower serum level and potentially a reduction in efficacy.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Trimethadione.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Trimethadione.Approved, Investigational, Vet Approved
OxypertineThe risk or severity of adverse effects can be increased when Trimethadione is combined with Oxypertine.Experimental
OxyphenisatinThe therapeutic efficacy of Oxyphenisatin can be decreased when used in combination with Trimethadione.Investigational, Withdrawn
OxytetracyclineThe risk or severity of adverse effects can be increased when Trimethadione is combined with Oxytetracycline.Approved, Investigational, Vet Approved
PalbociclibThe serum concentration of Trimethadione can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneThe risk or severity of hypotension can be increased when Paliperidone is combined with Trimethadione.Approved
PalonosetronThe risk or severity of adverse effects can be increased when Trimethadione is combined with Palonosetron.Approved, Investigational
PancuroniumTrimethadione may increase the neuromuscular blocking activities of Pancuronium.Approved
ParaldehydeTrimethadione may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParamethadioneThe risk or severity of adverse effects can be increased when Trimethadione is combined with Paramethadione.Approved
PargylineThe risk or severity of adverse effects can be increased when Pargyline is combined with Trimethadione.Approved
ParomomycinThe risk or severity of adverse effects can be increased when Trimethadione is combined with Paromomycin.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Trimethadione is combined with Paroxetine.Approved, Investigational
PeldesineTrimethadione may increase the excretion rate of Peldesine which could result in a lower serum level and potentially a reduction in efficacy.Experimental, Investigational
PemetrexedTrimethadione may increase the excretion rate of Pemetrexed which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
PenbutololThe risk or severity of adverse effects can be increased when Trimethadione is combined with Penbutolol.Approved, Investigational
PenciclovirTrimethadione may increase the excretion rate of Penciclovir which could result in a lower serum level and potentially a reduction in efficacy.Approved
PenfluridolThe risk or severity of adverse effects can be increased when Penfluridol is combined with Trimethadione.Experimental
PenimepicyclineThe risk or severity of adverse effects can be increased when Trimethadione is combined with Penimepicycline.Experimental
PentaerithritylThe therapeutic efficacy of Pentaerithrityl can be decreased when used in combination with Trimethadione.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Trimethadione.Approved, Vet Approved
PentifyllineTrimethadione may increase the excretion rate of Pentifylline which could result in a lower serum level and potentially a reduction in efficacy.Experimental
PentobarbitalThe metabolism of Trimethadione can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PentoxifyllineTrimethadione may increase the excretion rate of Pentoxifylline which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Trimethadione.Approved
PerazineThe risk or severity of adverse effects can be increased when Perazine is combined with Trimethadione.Approved, Investigational
PergolideThe risk or severity of adverse effects can be increased when Trimethadione is combined with Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Trimethadione.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Trimethadione.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Trimethadione.Approved
PhenacemideThe risk or severity of adverse effects can be increased when Trimethadione is combined with Phenacemide.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Trimethadione.Experimental
PhencyclidineThe risk or severity of adverse effects can be increased when Phencyclidine is combined with Trimethadione.Illicit
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Trimethadione.Approved
PhenethylamineThe risk or severity of adverse effects can be increased when Phenethylamine is combined with Trimethadione.Experimental
PheneturideThe risk or severity of adverse effects can be increased when Trimethadione is combined with Pheneturide.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Phenibut is combined with Trimethadione.Experimental
PheniprazineThe risk or severity of adverse effects can be increased when Pheniprazine is combined with Trimethadione.Withdrawn
PhenobarbitalThe metabolism of Trimethadione can be increased when combined with Phenobarbital.Approved, Investigational
PhenolphthaleinThe therapeutic efficacy of Phenolphthalein can be decreased when used in combination with Trimethadione.Approved, Withdrawn
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Trimethadione.Experimental
PhenoxybenzamineThe risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Trimethadione.Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Phenoxypropazine is combined with Trimethadione.Withdrawn
PhenprobamateThe risk or severity of adverse effects can be increased when Trimethadione is combined with Phenprobamate.Experimental
PhensuximideThe risk or severity of adverse effects can be increased when Trimethadione is combined with Phensuximide.Approved
PhentermineThe risk or severity of adverse effects can be increased when Trimethadione is combined with Phentermine.Approved, Illicit
PhentolamineThe risk or severity of hypotension can be increased when Phentolamine is combined with Trimethadione.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Trimethadione.Approved, Vet Approved
PiclozotanThe risk or severity of adverse effects can be increased when Trimethadione is combined with Piclozotan.Investigational
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Trimethadione.Approved
PimavanserinThe risk or severity of adverse effects can be increased when Trimethadione is combined with Pimavanserin.Approved, Investigational
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Trimethadione.Approved
PinazepamThe risk or severity of adverse effects can be increased when Pinazepam is combined with Trimethadione.Experimental
PindololThe risk or severity of adverse effects can be increased when Trimethadione is combined with Pindolol.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Trimethadione.Approved, Investigational
PipecuroniumTrimethadione may increase the neuromuscular blocking activities of Pipecuronium.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Trimethadione.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Trimethadione.Approved, Investigational
PirlimycinThe risk or severity of adverse effects can be increased when Trimethadione is combined with Pirlimycin.Vet Approved
PirlindoleThe risk or severity of adverse effects can be increased when Pirlindole is combined with Trimethadione.Approved
PitolisantThe serum concentration of Trimethadione can be decreased when it is combined with Pitolisant.Approved, Investigational
PivagabineThe risk or severity of adverse effects can be increased when Pivagabine is combined with Trimethadione.Investigational
PivhydrazineThe risk or severity of adverse effects can be increased when Pivhydrazine is combined with Trimethadione.Withdrawn
PizotifenThe risk or severity of hypotension can be increased when Pizotifen is combined with Trimethadione.Approved
Plantago seedThe therapeutic efficacy of Plantago seed can be decreased when used in combination with Trimethadione.Approved, Investigational
PlazomicinThe risk or severity of adverse effects can be increased when Trimethadione is combined with Plazomicin.Approved, Investigational
PlecanatideThe therapeutic efficacy of Plecanatide can be decreased when used in combination with Trimethadione.Approved, Investigational
PolycarbophilThe therapeutic efficacy of Polycarbophil can be decreased when used in combination with Trimethadione.Approved
Polyethylene glycolThe therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Trimethadione.Approved, Vet Approved
Polymyxin B SulfateThe risk or severity of adverse effects can be increased when Trimethadione is combined with Polymyxin B Sulfate.Approved, Vet Approved
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Trimethadione.Approved
PosaconazoleThe metabolism of Trimethadione can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
Potassium acetateThe therapeutic efficacy of Potassium acetate can be decreased when used in combination with Trimethadione.Approved, Investigational
PramipexoleTrimethadione may increase the sedative activities of Pramipexole.Approved, Investigational
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Trimethadione.Approved, Illicit
PrazosinThe risk or severity of hypotension can be increased when Prazosin is combined with Trimethadione.Approved
PregabalinThe therapeutic efficacy of Trimethadione can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PridinolThe risk or severity of adverse effects can be increased when Trimethadione is combined with Pridinol.Experimental
PrimidoneThe metabolism of Trimethadione can be increased when combined with Primidone.Approved, Vet Approved
ProcainamideThe risk or severity of adverse effects can be increased when Trimethadione is combined with Procainamide.Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Trimethadione.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Trimethadione.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Trimethadione.Approved, Vet Approved
ProgabideThe risk or severity of adverse effects can be increased when Progabide is combined with Trimethadione.Approved, Investigational
PromazineThe risk or severity of hypotension can be increased when Promazine is combined with Trimethadione.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Trimethadione.Approved, Investigational
PropanididThe risk or severity of adverse effects can be increased when Propanidid is combined with Trimethadione.Experimental
PropentofyllineTrimethadione may increase the excretion rate of Propentofylline which could result in a lower serum level and potentially a reduction in efficacy.Investigational
PropericiazineThe risk or severity of hypotension can be increased when Propericiazine is combined with Trimethadione.Approved, Investigational
PropiomazineThe risk or severity of hypotension can be increased when Propiomazine is combined with Trimethadione.Approved
PropiopromazineThe risk or severity of adverse effects can be increased when Trimethadione is combined with Propiopromazine.Vet Approved
PropiverineThe risk or severity of hypotension can be increased when Propiverine is combined with Trimethadione.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Trimethadione.Approved, Investigational, Vet Approved
ProthipendylThe risk or severity of adverse effects can be increased when Trimethadione is combined with Prothipendyl.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Trimethadione.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Proxibarbal is combined with Trimethadione.Experimental
ProxyphyllineTrimethadione may increase the excretion rate of Proxyphylline which could result in a lower serum level and potentially a reduction in efficacy.Experimental
PrucaloprideThe therapeutic efficacy of Prucalopride can be decreased when used in combination with Trimethadione.Approved
PRX-08066The risk or severity of adverse effects can be increased when Trimethadione is combined with PRX-08066.Investigational
PseudoephedrineThe risk or severity of adverse effects can be increased when Trimethadione is combined with Pseudoephedrine.Approved
PsilocybineThe risk or severity of adverse effects can be increased when Psilocybine is combined with Trimethadione.Investigational
PuromycinThe risk or severity of adverse effects can be increased when Trimethadione is combined with Puromycin.Experimental
PyrantelThe risk or severity of adverse effects can be increased when Trimethadione is combined with Pyrantel.Approved, Vet Approved
PyrithyldioneThe risk or severity of adverse effects can be increased when Pyrithyldione is combined with Trimethadione.Experimental
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Trimethadione.Approved, Illicit
QuetiapineThe risk or severity of hypotension can be increased when Quetiapine is combined with Trimethadione.Approved
QuinidineThe risk or severity of hypotension can be increased when Quinidine is combined with Trimethadione.Approved, Investigational
QuinineThe metabolism of Trimethadione can be increased when combined with Quinine.Approved
QuinupramineThe risk or severity of adverse effects can be increased when Quinupramine is combined with Trimethadione.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Raclopride is combined with Trimethadione.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Trimethadione is combined with Ramelteon.Approved, Investigational
RamosetronThe risk or severity of adverse effects can be increased when Trimethadione is combined with Ramosetron.Approved, Investigational
RapacuroniumTrimethadione may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Trimethadione.Approved
RavuconazoleThe therapeutic efficacy of Ravuconazole can be increased when used in combination with Trimethadione.Investigational
ReboxetineThe risk or severity of adverse effects can be increased when Reboxetine is combined with Trimethadione.Approved, Investigational
RemacemideThe risk or severity of adverse effects can be increased when Trimethadione is combined with Remacemide.Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Trimethadione.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Trimethadione.Approved, Withdrawn
RenzaprideThe risk or severity of adverse effects can be increased when Trimethadione is combined with Renzapride.Investigational
RepinotanThe risk or severity of adverse effects can be increased when Trimethadione is combined with Repinotan.Investigational
ReposalThe risk or severity of adverse effects can be increased when Reposal is combined with Trimethadione.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Trimethadione.Approved, Investigational
RibostamycinThe risk or severity of adverse effects can be increased when Trimethadione is combined with Ribostamycin.Approved, Investigational
RifampicinThe metabolism of Trimethadione can be increased when combined with Rifampicin.Approved
RifamycinThe metabolism of Trimethadione can be increased when combined with Rifamycin.Investigational
RifapentineThe metabolism of Trimethadione can be increased when combined with Rifapentine.Approved, Investigational
RifaximinThe metabolism of Trimethadione can be increased when combined with Rifaximin.Approved, Investigational
RiluzoleThe risk or severity of adverse effects can be increased when Trimethadione is combined with Riluzole.Approved, Investigational
RimexoloneThe metabolism of Trimethadione can be increased when combined with Rimexolone.Approved
RisperidoneThe risk or severity of hypotension can be increased when Risperidone is combined with Trimethadione.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Trimethadione is combined with Ritanserin.Investigational
RitonavirThe metabolism of Trimethadione can be decreased when combined with Ritonavir.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Trimethadione is combined with Rizatriptan.Approved
RocuroniumTrimethadione may increase the neuromuscular blocking activities of Rocuronium.Approved
RolipramThe risk or severity of adverse effects can be increased when Rolipram is combined with Trimethadione.Investigational
RolitetracyclineThe risk or severity of adverse effects can be increased when Trimethadione is combined with Rolitetracycline.Approved
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Trimethadione.Vet Approved
RopiniroleTrimethadione may increase the sedative activities of Ropinirole.Approved, Investigational
RotigotineTrimethadione may increase the sedative activities of Rotigotine.Approved
RP-5063The risk or severity of adverse effects can be increased when Trimethadione is combined with RP-5063.Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Trimethadione.Approved
SafinamideThe risk or severity of adverse effects can be increased when Trimethadione is combined with Safinamide.Approved, Investigational
SafrazineThe risk or severity of adverse effects can be increased when Safrazine is combined with Trimethadione.Withdrawn
SaquinavirThe metabolism of Trimethadione can be decreased when combined with Saquinavir.Approved, Investigational
SaredutantThe risk or severity of adverse effects can be increased when Saredutant is combined with Trimethadione.Investigational
SarilumabThe therapeutic efficacy of Trimethadione can be decreased when used in combination with Sarilumab.Approved, Investigational
SarpogrelateThe risk or severity of adverse effects can be increased when Trimethadione is combined with Sarpogrelate.Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Trimethadione.Approved, Investigational
SecobarbitalThe metabolism of Trimethadione can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Trimethadione.Approved, Investigational, Vet Approved
SennosidesThe therapeutic efficacy of Sennosides can be decreased when used in combination with Trimethadione.Approved
SerotoninThe risk or severity of adverse effects can be increased when Trimethadione is combined with Serotonin.Investigational, Nutraceutical
SertaconazoleThe therapeutic efficacy of Sertaconazole can be increased when used in combination with Trimethadione.Approved, Investigational
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Trimethadione.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Trimethadione is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Trimethadione.Approved, Vet Approved
SibutramineThe risk or severity of adverse effects can be increased when Sibutramine is combined with Trimethadione.Approved, Illicit, Investigational, Withdrawn
SilodosinThe risk or severity of hypotension can be increased when Silodosin is combined with Trimethadione.Approved
SiltuximabThe serum concentration of Trimethadione can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Trimethadione can be increased when it is combined with Simeprevir.Approved
SisomicinThe risk or severity of adverse effects can be increased when Trimethadione is combined with Sisomicin.Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Trimethadione.Approved
Sodium phosphate, monobasicThe therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Trimethadione.Approved
Sodium sulfateThe therapeutic efficacy of Sodium sulfate can be decreased when used in combination with Trimethadione.Approved, Vet Approved
Sodium tartrateThe therapeutic efficacy of Sodium tartrate can be decreased when used in combination with Trimethadione.Approved
SorbitolThe therapeutic efficacy of Sorbitol can be decreased when used in combination with Trimethadione.Approved
St. John's WortThe serum concentration of Trimethadione can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Trimethadione can be increased when it is combined with Stiripentol.Approved
StreptomycinThe risk or severity of adverse effects can be increased when Trimethadione is combined with Streptomycin.Approved, Vet Approved
StyramateThe risk or severity of adverse effects can be increased when Trimethadione is combined with Styramate.Experimental
SuccinylcholineThe risk or severity of adverse effects can be increased when Trimethadione is combined with Succinylcholine.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Trimethadione.Approved, Investigational
SulconazoleThe therapeutic efficacy of Sulconazole can be increased when used in combination with Trimethadione.Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Trimethadione.Approved, Investigational
SulthiameThe risk or severity of adverse effects can be increased when Trimethadione is combined with Sulthiame.Experimental
SultoprideThe risk or severity of adverse effects can be increased when Sultopride is combined with Trimethadione.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Trimethadione is combined with Sumatriptan.Approved, Investigational
SuvorexantTrimethadione may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
TalbutalThe risk or severity of adverse effects can be increased when Talbutal is combined with Trimethadione.Approved, Illicit
TalopramThe risk or severity of adverse effects can be increased when Trimethadione is combined with Talopram.Experimental
TamsulosinThe risk or severity of hypotension can be increased when Tamsulosin is combined with Trimethadione.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Tandospirone is combined with Trimethadione.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Trimethadione.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Trimethadione is combined with Tasimelteon.Approved, Investigational
TD-8954The risk or severity of adverse effects can be increased when Trimethadione is combined with TD-8954.Investigational
Tedizolid phosphateThe risk or severity of adverse effects can be increased when Trimethadione is combined with Tedizolid phosphate.Approved
TegaserodThe risk or severity of adverse effects can be increased when Trimethadione is combined with Tegaserod.Approved, Investigational, Withdrawn
TelaprevirThe metabolism of Trimethadione can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Trimethadione can be decreased when combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Trimethadione.Approved, Investigational
TerazosinThe risk or severity of hypotension can be increased when Terazosin is combined with Trimethadione.Approved
TerconazoleThe therapeutic efficacy of Terconazole can be increased when used in combination with Trimethadione.Approved
TetracyclineThe risk or severity of adverse effects can be increased when Trimethadione is combined with Tetracycline.Approved, Vet Approved
TetrahydrocannabivarinThe risk or severity of adverse effects can be increased when Trimethadione is combined with Tetrahydrocannabivarin.Investigational
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Trimethadione.Investigational
TetrazepamThe risk or severity of adverse effects can be increased when Trimethadione is combined with Tetrazepam.Experimental
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Trimethadione.Investigational
ThalidomideTrimethadione may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheobromineTrimethadione may increase the excretion rate of Theobromine which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
TheodrenalineTrimethadione may increase the excretion rate of Theodrenaline which could result in a lower serum level and potentially a reduction in efficacy.Investigational
ThiamylalThe metabolism of Trimethadione can be increased when combined with Thiamylal.Approved, Vet Approved
ThiazinamThe risk or severity of adverse effects can be increased when Trimethadione is combined with Thiazinam.Experimental
ThiethylperazineThe risk or severity of adverse effects can be increased when Trimethadione is combined with Thiethylperazine.Withdrawn
ThiocolchicosideThe risk or severity of adverse effects can be increased when Trimethadione is combined with Thiocolchicoside.Approved, Investigational
ThiopentalThe metabolism of Trimethadione can be increased when combined with Thiopental.Approved, Vet Approved
ThiopropazateThe risk or severity of adverse effects can be increased when Trimethadione is combined with Thiopropazate.Experimental
ThioproperazineThe risk or severity of hypotension can be increased when Thioproperazine is combined with Trimethadione.Approved
ThioridazineThe risk or severity of hypotension can be increased when Thioridazine is combined with Trimethadione.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Trimethadione.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Trimethadione.Approved, Investigational
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Trimethadione.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Tiapride is combined with Trimethadione.Approved, Investigational
TigecyclineThe risk or severity of adverse effects can be increased when Trimethadione is combined with Tigecycline.Approved
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Trimethadione.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Trimethadione.Experimental
TioconazoleThe therapeutic efficacy of Tioconazole can be increased when used in combination with Trimethadione.Approved
TipranavirThe metabolism of Trimethadione can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Trimethadione.Approved, Investigational
TobramycinThe risk or severity of adverse effects can be increased when Trimethadione is combined with Tobramycin.Approved, Investigational
TocilizumabThe serum concentration of Trimethadione can be decreased when it is combined with Tocilizumab.Approved
TofisopamThe risk or severity of adverse effects can be increased when Tofisopam is combined with Trimethadione.Approved
TolazolineThe risk or severity of hypotension can be increased when Tolazoline is combined with Trimethadione.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Trimethadione.Approved, Withdrawn
ToloxatoneThe risk or severity of adverse effects can be increased when Toloxatone is combined with Trimethadione.Approved
TolperisoneThe risk or severity of adverse effects can be increased when Trimethadione is combined with Tolperisone.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Trimethadione.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Trimethadione.Approved, Investigational
TramiprosateThe risk or severity of adverse effects can be increased when Trimethadione is combined with Tramiprosate.Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Trimethadione.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Trimethadione is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Trimethadione.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Tricaine methanesulfonate is combined with Trimethadione.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Trichloroethylene is combined with Trimethadione.Approved
TriclofosThe risk or severity of adverse effects can be increased when Triclofos is combined with Trimethadione.Withdrawn
TrifluoperazineThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Trimethadione.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Trifluperidol is combined with Trimethadione.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Trimethadione.Approved, Vet Approved
TrimazosinThe risk or severity of hypotension can be increased when Trimazosin is combined with Trimethadione.Experimental
TrimipramineThe risk or severity of hypotension can be increased when Trimipramine is combined with Trimethadione.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Trimethadione.Approved
TroleandomycinThe metabolism of Trimethadione can be decreased when combined with Troleandomycin.Approved
TropisetronThe risk or severity of adverse effects can be increased when Trimethadione is combined with Tropisetron.Approved, Investigational
TubocurarineTrimethadione may increase the neuromuscular blocking activities of Tubocurarine.Approved
UrapidilThe risk or severity of hypotension can be increased when Urapidil is combined with Trimethadione.Investigational
Uric AcidTrimethadione may increase the excretion rate of Uric Acid which could result in a lower serum level and potentially a reduction in efficacy.Experimental, Investigational
VabicaserinThe risk or severity of adverse effects can be increased when Trimethadione is combined with Vabicaserin.Investigational
ValaciclovirTrimethadione may increase the excretion rate of Valaciclovir which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
ValerianThe risk or severity of adverse effects can be increased when Valerian is combined with Trimethadione.Approved, Experimental, Investigational
ValganciclovirTrimethadione may increase the excretion rate of Valganciclovir which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
ValnoctamideThe risk or severity of adverse effects can be increased when Valnoctamide is combined with Trimethadione.Investigational
ValomaciclovirTrimethadione may increase the excretion rate of Valomaciclovir which could result in a lower serum level and potentially a reduction in efficacy.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Trimethadione.Approved, Investigational
ValpromideThe risk or severity of adverse effects can be increased when Trimethadione is combined with Valpromide.Experimental
VancomycinThe risk or severity of adverse effects can be increased when Trimethadione is combined with Vancomycin.Approved
VecuroniumTrimethadione may increase the neuromuscular blocking activities of Vecuronium.Approved
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Trimethadione.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Trimethadione is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Veralipride is combined with Trimethadione.Experimental
VerapamilThe risk or severity of hypotension can be increased when Verapamil is combined with Trimethadione.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Trimethadione.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Trimethadione.Approved
ViloxazineThe risk or severity of adverse effects can be increased when Viloxazine is combined with Trimethadione.Approved, Investigational, Withdrawn
VinbarbitalThe risk or severity of adverse effects can be increased when Vinbarbital is combined with Trimethadione.Experimental
VinpocetineThe risk or severity of adverse effects can be increased when Trimethadione is combined with Vinpocetine.Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Vinyl ether is combined with Trimethadione.Experimental
VinylbitalThe risk or severity of adverse effects can be increased when Vinylbital is combined with Trimethadione.Experimental
VoriconazoleThe metabolism of Trimethadione can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Trimethadione.Approved, Investigational
WortmanninThe risk or severity of adverse effects can be increased when Trimethadione is combined with Wortmannin.Experimental
XanthineTrimethadione may increase the excretion rate of Xanthine which could result in a lower serum level and potentially a reduction in efficacy.Experimental
XP19986The risk or severity of adverse effects can be increased when Trimethadione is combined with XP19986.Investigational
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Trimethadione.Vet Approved
YKP-1358The risk or severity of adverse effects can be increased when Trimethadione is combined with YKP-1358.Investigational
YohimbineThe risk or severity of adverse effects can be increased when Trimethadione is combined with Yohimbine.Approved, Investigational, Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Trimethadione.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Trimethadione.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Trimethadione is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of hypotension can be increased when Ziprasidone is combined with Trimethadione.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Trimethadione.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Trimethadione is combined with Zolmitriptan.Approved, Investigational
ZolpidemTrimethadione may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Trimethadione.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Trimethadione.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Trimethadione.Approved, Investigational, Withdrawn
ZuclopenthixolThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Trimethadione.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB0014491
KEGG Drug
D00392
PubChem Compound
5576
PubChem Substance
46504478
ChemSpider
5374
BindingDB
50019167
ChEBI
9727
ChEMBL
CHEMBL695
Therapeutic Targets Database
DAP001265
PharmGKB
PA164744924
Drugs.com
Drugs.com Drug Page
Wikipedia
Trimethadione
ATC Codes
N03AC02 — Trimethadione

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
  • Abbott laboratories pharmaceutical products div
Packagers
  • Abbott Laboratories Ltd.
Dosage forms
FormRouteStrength
Tablet, chewableOral150 mg/1
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)46 °CPhysProp
water solubility5E+004 mg/LMERCK INDEX (1996)
logP0Not Available
Predicted Properties
PropertyValueSource
Water Solubility212.0 mg/mLALOGPS
logP0.07ALOGPS
logP0.5ChemAxon
logS0.17ALOGPS
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area46.61 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity33.2 m3·mol-1ChemAxon
Polarizability13.59 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9954
Blood Brain Barrier+0.9479
Caco-2 permeable+0.5287
P-glycoprotein substrateNon-substrate0.8304
P-glycoprotein inhibitor INon-inhibitor0.6154
P-glycoprotein inhibitor IINon-inhibitor0.8382
Renal organic cation transporterNon-inhibitor0.9503
CYP450 2C9 substrateNon-substrate0.8289
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.5881
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.9694
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9361
Ames testNon AMES toxic0.6493
CarcinogenicityNon-carcinogens0.8515
BiodegradationNot ready biodegradable0.7859
Rat acute toxicity1.8563 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9961
hERG inhibition (predictor II)Non-inhibitor0.9775
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (7.69 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-0a4l-8900000000-43db0866b0f6797cbff6
GC-MS Spectrum - CI-BGC-MSsplash10-0006-1900000000-5560efcfc7260e1dcfef
Mass Spectrum (Electron Ionization)MSsplash10-0006-9200000000-46082deb9c636fb8f625
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as oxazolidinediones. These are compounds containing an oxazolidine ring which bears two ketones.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Azolidines
Sub Class
Oxazolidines
Direct Parent
Oxazolidinediones
Alternative Parents
Dicarboximides / Carbamate esters / Organic carbonic acids and derivatives / Oxacyclic compounds / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Oxazolidinedione / Dicarboximide / Carbamic acid ester / Carbonic acid derivative / Oxacycle / Azacycle / Carboxylic acid derivative / Hydrocarbon derivative / Organopnictogen compound / Organic oxygen compound
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Scaffold protein binding
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1G
Uniprot ID
O43497
Uniprot Name
Voltage-dependent T-type calcium channel subunit alpha-1G
Molecular Weight
262468.62 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Shen H, Zhang B, Shin JH, Lei D, Du Y, Gao X, Wang Q, Ohlemiller KK, Piccirillo J, Bao J: Prophylactic and therapeutic functions of T-type calcium blockers against noise-induced hearing loss. Hear Res. 2007 Apr;226(1-2):52-60. Epub 2006 Dec 31. [PubMed:17291698]
  4. Barton ME, Eberle EL, Shannon HE: The antihyperalgesic effects of the T-type calcium channel blockers ethosuximide, trimethadione, and mibefradil. Eur J Pharmacol. 2005 Oct 3;521(1-3):79-85. Epub 2005 Sep 19. [PubMed:16171802]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
Gene Name
CYP2E1
Uniprot ID
P05181
Uniprot Name
Cytochrome P450 2E1
Molecular Weight
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Tanaka E, Kurata N, Yasuhara H: Involvement of cytochrome P450 2C9, 2E1 and 3A4 in trimethadione N-demethylation in human microsomes. J Clin Pharm Ther. 2003 Dec;28(6):493-6. [PubMed:14651673]
  3. Kurata N, Nishimura Y, Iwase M, Fischer NE, Tang BK, Inaba T, Yasuhara H: Trimethadione metabolism by human liver cytochrome P450: evidence for the involvement of CYP2E1. Xenobiotica. 1998 Nov;28(11):1041-7. [PubMed:9879636]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Tanaka E, Kurata N, Yasuhara H: Involvement of cytochrome P450 2C9, 2E1 and 3A4 in trimethadione N-demethylation in human microsomes. J Clin Pharm Ther. 2003 Dec;28(6):493-6. [PubMed:14651673]
  3. Kurata N, Nishimura Y, Iwase M, Fischer NE, Tang BK, Inaba T, Yasuhara H: Trimethadione metabolism by human liver cytochrome P450: evidence for the involvement of CYP2E1. Xenobiotica. 1998 Nov;28(11):1041-7. [PubMed:9879636]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Kurata N, Nishimura Y, Iwase M, Fischer NE, Tang BK, Inaba T, Yasuhara H: Trimethadione metabolism by human liver cytochrome P450: evidence for the involvement of CYP2E1. Xenobiotica. 1998 Nov;28(11):1041-7. [PubMed:9879636]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Tanaka E, Kurata N, Yasuhara H: Involvement of cytochrome P450 2C9, 2E1 and 3A4 in trimethadione N-demethylation in human microsomes. J Clin Pharm Ther. 2003 Dec;28(6):493-6. [PubMed:14651673]
  3. Kurata N, Nishimura Y, Iwase M, Fischer NE, Tang BK, Inaba T, Yasuhara H: Trimethadione metabolism by human liver cytochrome P450: evidence for the involvement of CYP2E1. Xenobiotica. 1998 Nov;28(11):1041-7. [PubMed:9879636]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Kurata N, Nishimura Y, Iwase M, Fischer NE, Tang BK, Inaba T, Yasuhara H: Trimethadione metabolism by human liver cytochrome P450: evidence for the involvement of CYP2E1. Xenobiotica. 1998 Nov;28(11):1041-7. [PubMed:9879636]

Drug created on June 13, 2005 07:24 / Updated on August 02, 2018 04:19